NEW YORK, NY / ACCESSWIRE / December 4, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint Pharmaceuticals (“Eyepoint” or the “Company”) (NASDAQ:EYPT).
If you suffered losses exceeding $50,000 investing in Eyepoint stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EYPT.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
On August 30, 2022, EyePoint announced that it had received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts. The subpoena demanded documents covering the Company’s sales practices for its postoperative inflammation treatment, DEXYCU. Following this news, shares of EyePoint fell sharply in after-hours trading.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE: Faruqi & Faruqi, LLP
View source version on accesswire.com:
https://www.accesswire.com/729934/Securities-Litigation-Partner-James-Josh-Wilson-Encourages-Investors-Who-Suffered-Losses-Exceeding-50000-In-Eyepoint-To-Contact-Him-Directly-To-Discuss-Their-Options
